Three nitrogen atoms turn old kinase inhibitors into new targetable remedy

This study presents a novel light-targeted therapeutic strategy using photoactivatable VEGFR2 inhibitors (EYE1090 and EYE1118) that, upon oral administration and green light activation, significantly enhance retinal drug efficacy and reduce systemic toxicity for treating pathological eye neovascularization.

The Gist

Imagine your eyes are like a high-tech camera. Sometimes, due to diseases like "wet" macular degeneration or diabetic retinopathy, the camera starts leaking fluid and growing messy, tangled wires (new blood vessels) where they shouldn't be. This ruins your vision.

Currently, the only way to fix this is to stick a needle directly into the eye every few weeks to inject a drug that stops the growth. It's painful, scary, and hard to keep up with.

This paper introduces a brilliant new idea: What if we could swallow a pill, but the drug only "wakes up" when it sees the light inside your eye?

Here is the story of how they did it, explained simply:

1. The Problem with Old Drugs

Scientists have had powerful drugs (like Sunitinib and Vorolanib) that stop bad blood vessel growth. They work great for cancer, but they are too dangerous to take as a daily pill for eye diseases.

• The Analogy: Think of these drugs like a very strong, aggressive gardener. If you release them into your whole body, they will kill the weeds (bad blood vessels) in your eye, but they will also trample your flowers (your liver and other organs). In fact, one of these drugs (Vorolanib) was stopped in clinical trials because it hurt people's livers too much.

2. The "Magic Switch" (The Solution)

The researchers took these old drugs and added a tiny, special chemical "switch" to them. They call this azido-functionalization.

• The Analogy: Imagine putting a "sleeping" spell on that aggressive gardener. While the gardener is asleep (in the dark), they are still somewhat effective, but mostly harmless. However, they have a special pair of sunglasses that only open when they see green light.
• How it works: When you swallow the pill, it travels through your blood. It's mostly quiet. But when it reaches your eye, the natural light that enters your eye hits the drug. The "switch" flips, and the drug instantly becomes a super-powerful, sticky weapon that locks onto the bad blood vessels and stops them dead in their tracks.

3. The "Spotlight" Effect

The human eye is a perfect machine for focusing light. When you look at something, your eye gathers light and focuses it intensely on the retina (the back of the eye).

• The Analogy: This is like using a magnifying glass to start a fire. The sun's light is weak on a cloudy day, but if you focus it through a lens, it gets hot enough to burn.
• The Result: Because the eye focuses light so well, the drug gets "super-charged" only inside the eye. In the rest of your body (where there is no focused light), the drug stays mostly asleep. This means you can take a much smaller dose of the drug, and it won't hurt your liver or other organs.

4. What They Found

The scientists tested this on cells and mice, and the results were amazing:

• In the Dark: The drugs worked okay, but not great.
• In the Light: As soon as they shined a green light (the kind that can reach the back of the eye even in older people), the drugs became 10 to 30 times stronger.
• The Liver Test: They gave mice a huge dose of the drug (40 times the normal amount) and checked their livers. Even with that massive dose, the livers were perfectly healthy. This suggests that because the drug stays "asleep" until it hits the eye, it doesn't poison the body.
• The Eye Test: In mice with eye diseases, a tiny dose of the pill stopped the bad blood vessel growth and prevented vision loss.

5. Why This Matters

This is a game-changer for two reasons:

1. No More Needles: Instead of getting shots in the eye every month, patients might just take a daily pill and maybe wear special glasses or sit in the sun for a few minutes to "activate" the medicine.
2. Safety: It turns a dangerous drug into a safe one by making it work only where you need it.

In a nutshell: The researchers took old, dangerous drugs, put them to sleep, and gave them a "green light" key. Now, they only wake up and fight the disease when they are inside your eye, leaving the rest of your body safe and sound. It's like having a security guard who only wakes up when a burglar enters the specific room you are worried about, ignoring the rest of the house.

Technical Summary

1. Problem Statement

• Clinical Challenge: Pathological neovascularization in the eye (e.g., Age-Related Macular Degeneration [AMD] and Diabetic Retinopathy) is a leading cause of vision loss. Current gold-standard treatments rely on intravitreal injections of anti-VEGF biologics (e.g., aflibercept), which are invasive, require frequent administration, and carry procedural risks.
• Limitations of Small Molecules: Oral small-molecule tyrosine kinase inhibitors (TKIs) like sunitinib and vorolanib have shown efficacy in suppressing angiogenesis but suffer from severe systemic toxicity (particularly hepatobiliary toxicity) and narrow therapeutic windows. Vorolanib, despite promising ocular efficacy, failed in oral clinical trials for AMD due to liver toxicity.
• The Gap: There is a critical need for orally administered, small-molecule therapies that can target the retina specifically, minimizing systemic exposure and toxicity while avoiding the burden of eye injections.

2. Methodology

The authors developed a novel strategy termed "optotargeting," utilizing photoactivatable kinase inhibitors.

• Chemical Design:
  • Two new chemical entities (NCEs), EYE1090 and EYE1118, were engineered from the scaffolds of sunitinib and vorolanib, respectively.
  • Modification: An azido group (-N₃) was attached to the 5-position of the oxindole ring, and a chlorine atom was added to the 6-position. This azido-functionalization allows the molecules to act as photoaffinity probes.
  • Mechanism: In the dark, the compounds act as reversible inhibitors. Upon exposure to specific wavelengths of light (green/white), the azido group undergoes photolysis, generating a reactive nitrene species that forms a covalent bond with the VEGFR2 receptor, effectively "locking" the inhibitor to the target.
• In Vitro Assays:
  • Cell Viability: NIH/3T3 fibroblasts treated with compounds to assess cytotoxicity.
  • Luciferase Reporter Assay: HEK293 cells expressing VEGFR2/NFAT to measure signaling inhibition under dark vs. light conditions (White, Red, and Green LEDs).
  • Western Blotting: Analysis of VEGFR2 phosphorylation (Y951 and Y1175) to confirm target engagement.
  • Angiogenesis & Migration: Human Retinal Microvascular Endothelial Cells (HRMECs) were used for tubulogenesis (tube formation) and transwell migration assays, with and without light exposure.
• In Vivo Models:
  • Pharmacokinetics (PK): BALB/c mice (albino) received oral EYE1090. Groups were exposed to white light or kept in dim red light. Serum levels were measured via HPLC.
  • Retinal Permeability: Long Evans rats received oral EYE1090/EYE1118 (1 mg/kg) followed by intravitreal VEGF injection. Vascular leakage was quantified using the Evans Blue assay.
  • Choroidal Neovascularization (CNV): C57BL/6 mice (pigmented) underwent laser-induced CNV. Compounds were administered orally prophylactically (1 mg/kg). Lesion size was monitored via Indocyanine Green Angiography (ICGA).
  • Toxicity: Acute hepatotoxicity was assessed in BALB/c mice (40 mg/kg dose) via histology (H&E, PAS, Picrosirius Red staining).

3. Key Contributions

• Novel "Optotargeting" Strategy: The paper introduces a paradigm where systemically administered drugs are activated only at the target tissue (the retina) by natural light, leveraging the eye's anatomy to focus light onto the retina.
• Chemical Innovation: Demonstrates that azidation of established TKI scaffolds (sunitinib/vorolanib) creates photo-switchable inhibitors that retain potency in the dark but become significantly more potent (covalent binders) upon illumination.
• Overcoming Previous Failures: Addresses the specific failure of oral vorolanib in AMD by proposing a light-activated version that requires drastically lower systemic doses, potentially eliminating hepatotoxicity.

4. Key Results

• Enhanced Potency via Light:
  • EYE1090: IC₅₀ dropped from ~19 nM (dark) to ~2.2 nM (white light) and ~1.3 nM (green light) in VEGFR2 signaling assays.
  • EYE1118: IC₅₀ dropped from ~52 nM (dark) to ~6.5 nM (white light) and ~4.9 nM (green light).
  • Specificity: Red light (654 nm) had no effect, confirming the activation is wavelength-specific and dependent on the azido group's photolysis. Green light (516 nm), which penetrates the human retina effectively even in the elderly, showed the highest potentiation (up to 30-fold).
• Mechanism of Action:
  • Western blots confirmed that light exposure significantly reduced VEGF-induced phosphorylation of VEGFR2 (Y951 and Y1175), indicating successful covalent binding and receptor inhibition.
  • In HRMECs, light exposure significantly enhanced the inhibition of tube formation and cell migration compared to dark conditions.
• In Vivo Efficacy:
  • PK Study: In albino mice, white light exposure reduced serum EYE1090 levels by >50% compared to dark controls, suggesting rapid tissue uptake/activation in light-exposed areas.
  • Retinal Leakage: Both compounds (at 1 mg/kg) significantly suppressed VEGF-induced retinal leakage in rats. This dose is 10-fold lower than doses required for parental compounds in previous studies.
  • CNV Model: Prophylactic oral administration of EYE1090 and EYE1118 (1 mg/kg) significantly reduced CNV lesion size in mice by Day 5 and Day 7 compared to vehicle controls.
• Safety Profile:
  • Hepatotoxicity: Acute toxicity studies at 40 mg/kg (40x the therapeutic dose) showed no signs of liver damage (necrosis, fibrosis, or glycogen depletion) in either light or dark conditions. This contrasts sharply with the known hepatotoxicity of sunitinib and the clinical failure of oral vorolanib.
  • Cytotoxicity: EYE1090 and EYE1118 showed lower toxicity to fibroblasts than their parental compounds at high concentrations.

5. Significance

• Therapeutic Paradigm Shift: This study proposes a non-invasive, oral alternative to intravitreal injections for retinal diseases. By exploiting the eye's natural light-focusing ability, it achieves tissue-specific drug activation.
• Safety and Efficacy: The strategy allows for a massive reduction in systemic drug exposure (lowering the risk of off-target toxicity like liver failure) while maintaining or enhancing efficacy at the target site through covalent binding.
• Clinical Potential:
  • EYE1118 (vorolanib derivative) is highlighted as a prime candidate for clinical development for AMD and diabetic retinopathy, potentially reviving the oral route for this class of drugs.
  • EYE1090 (sunitinib derivative) shows promise for oncology, where light could be used to activate the drug in tumors during surgery or endoscopy, reducing systemic chemo-toxicity.
• Proof of Concept: The work validates the "azido-functionalization" approach for converting reversible kinase inhibitors into potent, light-targeted covalent drugs, opening a new avenue for "light-guided pharmacology."